Ophiomics develops in vitro diagnostic devices that utilize artificial intelligence and genomics to enhance early cancer detection and optimize treatment selection. Their technology integrates machine learning algorithms with clinical and biomarker data to improve decision-making for clinicians, ultimately aiming to enhance patient outcomes in oncology.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early cancer detection and treatment selection often rely on incomplete data, leading to suboptimal clinical decisions and potentially impacting patient outcomes. Clinicians need more precise and integrative tools to navigate the complexities of cancer diagnostics and treatment planning.
Solution
Ophiomics develops in vitro diagnostic (IVD) medical devices that leverage artificial intelligence and genomics to improve cancer diagnostics and treatment selection. Their technology integrates biomarker data with clinical variables through machine learning algorithms, creating solutions designed to support clinical decision-making at critical stages of the cancer patient journey. Ophiomics' products are designed to seamlessly integrate into routine clinical practice, ensuring accessibility and ease of adoption. The company's approach centers around addressing clinical questions and minimizing technical, clinical, and commercial uncertainties to maximize the chances of bringing impactful products to market.
Target Audience
Ophiomics' primary customers are clinicians in oncology seeking to enhance early cancer detection and optimize treatment selection, as well as clinical laboratories.
Features
- IVD medical devices integrating bioinformatics, artificial intelligence, and genomics
- Machine learning models that extract information from data and integrate diverse data types
- Focus on biomarker discovery and development centered around addressing clinical questions
- Products designed for seamless integration into routine clinical practice
- Re-usable Dx-oriented technological platforms to facilitate the development of new products